53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000665-32-NL
(EUCTR)
16/02/202221/10/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nipocalimab
Product Code: M281
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2Portugal;France;United States;Taiwan;Spain;Poland;Germany;Netherlands;Italy;Japan
2EUCTR2021-000665-32-DE
(EUCTR)
12/11/202127/07/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nipocalimab
Product Code: M281
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2Portugal;France;United States;Taiwan;Spain;Poland;Netherlands;Germany;Italy;Japan
3EUCTR2021-000665-32-IT
(EUCTR)
10/11/202108/09/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) - NA Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: nipocalimab
Product Code: [M281]
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
JANSSEN CILAG INTERNATIONAL NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2Portugal;France;United States;Taiwan;Spain;Poland;Netherlands;Germany;Japan;Italy
4EUCTR2021-000665-32-PT
(EUCTR)
09/11/202116/09/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nipocalimab
Product Code: M281
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2France;United States;Portugal;Taiwan;Spain;Poland;Netherlands;Germany;Italy;Japan
5EUCTR2021-000665-32-ES
(EUCTR)
26/10/202127/08/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS). Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nipocalimab
Product Code: M281
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2Portugal;France;United States;Taiwan;Poland;Spain;Netherlands;Germany;Italy;Japan
6EUCTR2021-000665-32-PL
(EUCTR)
16/10/202116/09/2021A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Primary Sjogren's Syndrome
MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Nipocalimab
Product Code: M281
INN or Proposed INN: nipocalimab
Other descriptive name: JNJ-80202135
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2Portugal;France;United States;Taiwan;Spain;Poland;Netherlands;Germany;Italy;Japan